Testing a new treatment for advanced pancreatic cancer
Part of Cancer, Digestive system clinical trials.
This trial tests combining endoscopic ultrasound-guided radiofrequency ablation with FOLFIRINOX chemotherapy for people with advanced pancreatic cancer that hasn't spread to other organs. It aims to see if this approach is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with locally advanced or borderline resectable pancreatic cancer (confirmed by a biopsy) and a team of doctors agrees.
- Your cancer has not spread to other parts of the body (no metastases).
- You have not had any previous cancer treatments (like surgery, chemotherapy, or radiation).
- You are in generally good health (able to do most daily activities) with a performance status of 0 or 1.
- Your tumor is at least 2 cm in size (using standard scans) and can be reached with an endoscopic ultrasound.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving a strong chemotherapy combination (mFOLFIRINOX) together with radiation therapy can help people with advanced pancreatic cancer who have normal CA19-9 levels. It aims to see if this approach is more effective for this specific group of patients.
This trial tests a combination of targeted radiation and two oral drugs (defactinib and avutometinib) for people with advanced pancreatic cancer that hasn't spread to distant organs. It may be an option if you've already had at least 2 months of chemo and your cancer is still locally advanced or borderline resectable.
This trial tests a combination of endoscopic ultrasound-guided heat ablation (RFA) and the immunotherapy drug pembrolizumab for people with locally advanced or metastatic pancreatic cancer that cannot be surgically removed. The goal is to see if this approach can shrink tumors and improve outcomes.
This early-phase trial is testing a new endoscopic (from inside the stomach) approach for pancreatic ductal adenocarcinoma that is locally advanced and cannot be removed with surgery. It may help some people who have already tried first chemotherapy and still have a tumor confined to the pancreas area (no spread).
This trial tests a combination of chemotherapy (mFOLFIRINOX) and radiation therapy for people with advanced pancreatic cancer that has stopped responding to chemotherapy and whose CA19-9 tumor marker levels are normal. The goal is to see if this approach can help when standard treatments are no longer working.
This trial tests a procedure that uses an endoscope and ultrasound to heat (radiofrequency ablate) pancreatic neuroendocrine tumors. It may help shrink tumors while aiming to be a less invasive option.
Hear when a new Pancreatic Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.